Acquired resistance to osimertinib in advanced lung cancer: A case report

被引：0

作者：

Xu, Jiayi ^{[1
,2
]}

Xu, Zikai ^{[1
]}

Hong, Jianwei ^{[2
,3
]}

Zhou, Xiaoyu ^{[1
]}

机构：

[1] Nantong Univ, Dept Resp & Crit Care Med, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Peoples R China

[2] Nantong Univ, Med Sch, Nantong 226001, Peoples R China

[3] Nantong Univ, Dept Gastroenterol, Affiliated Hosp, Nantong 226001, Peoples R China

来源：

ASIAN JOURNAL OF SURGERY | 2024年 / 47卷 / 08期

关键词：

D O I：

10.1016/j.asjsur.2024.04.116

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

引用

页码：3763 / 3764

页数：2

共 50 条

[1] Rhabdomyolysis in a patient with advanced lung cancer treated with osimertinib: a case report
Li, You
Liu, Yu
Zhao, Zichen
Zhang, Yan
TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (03) : 629 - 636
[2] Osimertinib/selpercatinibVarious toxicities and acquired resistance: case report
Reactions Weekly, 2022, 1906 (1) : 322 - 322
[3] How to overcome and circumvent acquired resistance to osimertinib or lazertinib in advanced EGFR mutant lung cancer?
Cho, Byoung Chul
ANNALS OF ONCOLOGY, 2023, 34 : S1378 - S1378
[4] Carboplatin/osimertinib/pemetrexedNephrotoxicity and acquired drug resistance: case report
Reactions Weekly, 2021, 1879 (1) : 89 - 89
[5] Afatinib/osimertinibSkin toxicity and acquired resistance to osimertinib: case report
Reactions Weekly, 2017, 1666 (1) : 18 - 18
[6] Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
Lee, Jiyun
Piotrowska, Zofia
Soo, Ross
Cho, Byoung Chul
Lim, Sun Min
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[7] Acquired resistance mechanism of osimertinib targeting EGFR in human lung cancer
Ciaramella, V.
Della Corte, C. M.
Barra, G.
Di Liello, R.
Viscardi, G.
Orditura, M.
Martinelli, E.
Ciardiello, F.
Morgillo, F.
ANNALS OF ONCOLOGY, 2018, 29
[8] OsimertinibSquamous cell transformation following acquired resistance to osimertinib: case report
Reactions Weekly, 2019, 1778 (1) : 348 - 348
[9] OsimertinibAcquired resistance to osimertinib therapy in lung adenocarcinoma: case report
Reactions Weekly, 2018, 1718 (1) : 176 - 176
[10] Gefitinib/osimertinib/pembrolizumabCytokine release syndrome and acquired drug resistance: case report
Reactions Weekly, 2022, 1909 (1) : 259 - 259

← 1 2 3 4 5 →